[go: up one dir, main page]

DK3768305T3 - Modificerede, onkolytiske adenovira - Google Patents

Modificerede, onkolytiske adenovira Download PDF

Info

Publication number
DK3768305T3
DK3768305T3 DK19712178.3T DK19712178T DK3768305T3 DK 3768305 T3 DK3768305 T3 DK 3768305T3 DK 19712178 T DK19712178 T DK 19712178T DK 3768305 T3 DK3768305 T3 DK 3768305T3
Authority
DK
Denmark
Prior art keywords
adenoviras
oncolytic
modified
oncolytic adenoviras
Prior art date
Application number
DK19712178.3T
Other languages
English (en)
Other versions
DK3768305T5 (da
Inventor
Tuuli Ranki
Sari Pesonen
Petri Priha
Erkko Ylösmäki
Vincenzo Cerullo
Beatriz Martins
Original Assignee
Valo Therapeutics Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valo Therapeutics Oy filed Critical Valo Therapeutics Oy
Publication of DK3768305T3 publication Critical patent/DK3768305T3/da
Application granted granted Critical
Publication of DK3768305T5 publication Critical patent/DK3768305T5/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/761Adenovirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001184Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001184Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188NY-ESO
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/80Vaccine for a specifically defined cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/80Vaccine for a specifically defined cancer
    • A61K2039/876Skin, melanoma
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK19712178.3T 2018-03-21 2019-03-19 Modificerede, onkolytiske adenovira DK3768305T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1804473.5A GB201804473D0 (en) 2018-03-21 2018-03-21 Modified oncolytic adenoviruses
GBGB1814867.6A GB201814867D0 (en) 2018-03-21 2018-09-13 Modified Oncolytic Adenoviruses
PCT/EP2019/056768 WO2019179977A1 (en) 2018-03-21 2019-03-19 Modified oncolytic adenoviruses

Publications (2)

Publication Number Publication Date
DK3768305T3 true DK3768305T3 (da) 2023-01-23
DK3768305T5 DK3768305T5 (da) 2024-08-19

Family

ID=62017873

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19712178.3T DK3768305T5 (da) 2018-03-21 2019-03-19 Modificerede, onkolytiske adenovira

Country Status (13)

Country Link
US (1) US20210017501A1 (da)
EP (1) EP3768305B1 (da)
JP (1) JP7417533B2 (da)
KR (1) KR102760462B1 (da)
CN (1) CN112118864B (da)
AU (1) AU2019239033B2 (da)
CA (1) CA3094131A1 (da)
DK (1) DK3768305T5 (da)
ES (1) ES2935745T3 (da)
FI (1) FI3768305T3 (da)
GB (2) GB201804473D0 (da)
WO (1) WO2019179977A1 (da)
ZA (1) ZA202005848B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6576326B2 (ja) 2013-03-14 2019-09-18 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍溶解性アデノウイルス組成物
KR20220163505A (ko) 2016-02-23 2022-12-09 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
AU2017222568B2 (en) 2016-02-23 2020-09-10 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
GB201804468D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy PeptiCRAd Cancer Therapy
CN112292449A (zh) 2018-04-09 2021-01-29 萨克生物研究学院 具有增强的复制特性的溶瘤腺病毒组合物
CN113699122B (zh) * 2021-08-31 2023-10-20 中国科学院大学宁波华美医院 一种多基因融合溶瘤腺病毒及其构建方法和应用
AU2022349649A1 (en) 2021-09-23 2024-04-04 Sagittarius Bio, Inc. Adenoviruses and methods for using adenoviruses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU711269B2 (en) * 1994-08-16 1999-10-07 Crucell Holland B.V. Recombinant vectors derived from adenovirus for use in gene therapy
US7829329B2 (en) * 1998-04-24 2010-11-09 Onyx Pharmaceuticals, Inc. Adenoviral vectors for treating disease
CA2376314A1 (en) * 1999-06-07 2000-12-14 The University Of British Columbia Apoptosis inhibition by adenovirus e3/6.7k
EP1218527A2 (en) * 1999-07-02 2002-07-03 Onyx Pharmaceuticals, Inc. Adenoviral vectors for treating disease
US8940290B2 (en) * 2008-10-31 2015-01-27 The Trustees Of The University Of Pennsylvania Simian adenoviruses SAdV-43, -45, -46, -47, -48, -49, and -50 and uses thereof
HUE031689T2 (en) * 2008-12-22 2017-07-28 Targovax Oy Oncolytic adenoviral vectors and related procedures and applications
RU2012107702A (ru) * 2009-07-31 2013-09-10 Пэксвэкс, Инк. Векторы на основе аденовирусов
AU2011306846B2 (en) * 2010-09-24 2015-05-14 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
SG10202004535PA (en) * 2013-04-18 2020-06-29 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
US10799568B2 (en) * 2014-05-19 2020-10-13 Valo Therapeutics Oy Modified adenoviruses for cancer vaccines development
TWI636271B (zh) * 2014-11-20 2018-09-21 力智電子股份有限公司 電池模組的電量量測裝置及方法
US10626377B2 (en) * 2016-01-08 2020-04-21 Replimune Limited Use of an oncolytic virus for the treatment of cancer
US11090344B2 (en) * 2016-05-27 2021-08-17 Dnatrix, Inc. Adenovirus and immunomodulator combination therapy
SI3293201T1 (sl) * 2016-09-12 2021-03-31 Targovax Oy Kombinacija zaviralcev adenovirusa in zaviralcev kontrolnih točk za zdravljenje raka
US10232053B2 (en) * 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
GB201804468D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy PeptiCRAd Cancer Therapy

Also Published As

Publication number Publication date
CN112118864A (zh) 2020-12-22
GB201804473D0 (en) 2018-05-02
CN112118864B (zh) 2024-06-25
JP7417533B2 (ja) 2024-01-18
KR20200135811A (ko) 2020-12-03
ES2935745T3 (es) 2023-03-09
FI3768305T3 (fi) 2023-01-31
JP2021518126A (ja) 2021-08-02
ZA202005848B (en) 2022-01-26
AU2019239033B2 (en) 2025-03-06
RU2020131337A (ru) 2022-04-28
WO2019179977A1 (en) 2019-09-26
GB201814867D0 (en) 2018-10-31
DK3768305T5 (da) 2024-08-19
BR112020019303A2 (pt) 2021-01-05
KR102760462B1 (ko) 2025-01-31
EP3768305B1 (en) 2022-11-30
CA3094131A1 (en) 2019-09-26
US20210017501A1 (en) 2021-01-21
EP3768305A1 (en) 2021-01-27
AU2019239033A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
IL282985B (en) Modified oncolytic viurs
EP3833739A4 (en) STRAIN OF AKKERMANSIA MUCINIPHILA
DK3768305T3 (da) Modificerede, onkolytiske adenovira
LT3652215T (lt) Pagerinta dvejopo savitumo polipeptido molekulė
DK3565568T3 (da) Ændret virus
DK3642340T3 (da) Modificeret L-asparaginase
HUE062816T2 (hu) Onkolitikus vakciniavírus
IL282178A (en) Products, uses & methods
DK3737403T3 (da) Modificerede adenovira
EP3713931C0 (en) 3-OXO-6-HETEROARYL-2-PHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDE
EP3919491C0 (en) AKT INHIBITOR
DK3946179T3 (da) Stomiposer
EP3967649C0 (en) LIPID NANOPARTICLE
EP3742771C0 (en) M2M SM-SR TO SM-DP NOTIFICATION
EP3703188A4 (en) HERMETIC TERMINAL
EP3975220A4 (en) Display panel
EP3625349A4 (en) MODIFIED VIRUSES
EP3789489A4 (en) ANTI-SWEEPER TYPE ONCOLYTIC VIRUS
EP3957391C0 (en) AGITATOR
EP4041256A4 (en) Oncolytic viruses that express multi-specific immune cell engagers
EP3965638C0 (en) VAGINAL SPECULUM
EP3962498A4 (en) Combination therapies
EP3624825A4 (en) RECOMBINANT ONCOLYTIC VIRUS
EP3724324C0 (en) CARBOXYESTERASE BIOCATALYSTS
EP4063289C0 (en) CROWN CAPSULE